Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subjective Evaluation of Inflow Pain: Extraneal vs Extraneal Physiological pH
2004-001390-26Phase 3Completed
- Sponsor
- Baxter
- Start
- Sep 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of icodextrin in end-stage kidney disease (ESKD) (2 arms), sponsored by Baxter. Primary endpoint: Inflow pain severity. Started Sep 2004; status: completed.
02
Drugs
icodextrin
03
Conditions
end-stage kidney disease (ESKD)
Beyond the preview
Go deeper on 2004-001390-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-001390-26.